Complication rates and costs of invasive lung cancer diagnostic tests may be higher than anticipated

Complication rates and costs of invasive lung cancer diagnostic tests may be higher than anticipated

Ya Chen Tina Shih, Ph.D.

Study underscores importance of sharing risks with patients considering lung cancer screening HOUSTON ― Complication rates following invasive diagnostic procedures for lung abnormalities were twice as high in the community setting compared to those reported in lung cancer screening trials, and associated downstream costs ranged from $6,320 to $56,845 on average, according to a new study from The University of Texas MD Anderson Cancer Center. The researchers believe the findings, published today in JAMA Internal Medicine, reinforce […]